Printer Friendly

CSMG Technologies Announces Live Tissue Connect Subsidiary to Present at Two Prestigious International Surgical Conferences.

CORPUS CHRISTI, Texas -- CSMG Technologies, Inc., (OTCBB: CTUM) focused on commercializing human live tissue bonding devices and renewable energy landfill gas production systems, announced its Live Tissue Connect subsidiary will present white papers at two prestigious international surgical conferences next month.

Clinical researcher Dr. Olexandr Linchevsky of Kiev, Ukraine will present a scientific white paper on WELDING OF PULMONARY TISSUE IN SPONTANEOUS PNEUMATHORAX OPERATION WITHOUT STAPLING at the 5th annual joint meeting of The European Association for Cardio-Thoracic Surgery and European Society of Thoracic Surgeons (AACTS/ESTS) in Stockholm, Sweden, September 9-13, 2006. For further information on AACTS,, and ESTS,

Dr. Sergiy Podpriatov, a clinical researcher, will present a white paper on "SUBMUCOSAL ELECTRIC WELDING OF THE COMPLICATED HEMORRHOIDS" at the European Society of Coloproctology (ESCP), in Lisbon, Spain, September 14-16, 2006. For further information on ESCP,

Donald S. Robbins, president and CEO of CSMG, said, " We are excited about the opportunity to be invited to present at these prestigious international conferences. These are our first international presentations for our Live Tissue Connect technology. We are beginning to show the global surgical and medical communities the versatility of the tissue welding technology. We continue to develop our technology, and procedures, that allow human tissue to be connected efficiently without the use of sutures, glues, sealant or staples."

About CSMG Technologies' Tissue Welding/Bonding Technology

Surgeons at 10 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 6,000 human surgeries using more than 70 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominal plasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S. and Australia patents have been issued, a patent in the European Union has been approved, and additional U.S. and foreign patents are pending.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG has three subsidiaries, Live Tissue Connect, Inc., CSMG Gastech, LLC and Anaerobic Farm Waste, Inc. For further information on CSMG Technologies and it's various subsidiaries, please visit our website at

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words ``may,'' ``would,'' ``will,'' ``expect,'' ``estimate,'' ``anticipate,'' ``believe,'' ``intend'' and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 7, 2006
Previous Article:Medtech Insight and Windhover Information's 2006 ``Investment in Innovation (In3) Europe: A Preview of Emerging Medical Technologies'' premier...
Next Article:Xerox Makeover Brings a Touch of High-Tech to Charlotte's 'Latin American Coalition' Offices.

Related Articles
CSMG Technologies Retains ROI Group Associates as Investor Relations Counsel.
CSMG Technologies Announces 450 Successful Lung Surgical Procedures Completed.
Transsphenoidal encephalocele in a neonate.
CSMG Technologies CEO Featured in Exclusive Interview with Wall Street Reporter; Live Tissue Connect Subsidiary, Focused On Commercialization Of...
CSMG Technologies Announces Live Tissue Connect Subsidiary to Present at Prestigious International Surgical Conference; Presenting at European...
CSMG Technologies Live Tissue Connect Subsidiary Completes Duct and Vessel Sealer Prototype.
CSMG Technologies Live Tissue Connect Technology Receives Strong Response from Bulgaria Medical Academy of Science.
CSMG Technologies Announces Live Tissue Connect Subsidiary Results at Prestigious International EATS/ESTS Surgical Conference.
CSMG Technologies Announces Breakthrough Tissue Welding for Human Laryngectomy and Chondrectomy Procedures.
Novel Intraoperative Probe Effective in Assessing Lumpectomy Margins, Elusive DCIS.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters